Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong

被引：0
|
作者：
Loong, H. H. [1 ]
Wong, C. K. H. [2 ]
Leung, L. K. S. [3 ]
Chan, C. P. K. [4 ]
Chang, A. [5 ]
Gibbs, M. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Novartis Oncol Hong Kong, Med Affairs, Hong Kong, Peoples R China
[5] Novartis Oncol Hong Kong, Market Access, Hong Kong, Peoples R China
[6] Novartis Oncol, Dubai, U Arab Emirates
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [42] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [43] THE MANAGEMENT AND COSTS OF LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN GREECE
    Kousoulakou, H.
    Boukovinas, I
    Georgoulias, V
    Kosmidis, P.
    Koumakis, G.
    Makrantonakis, P.
    Samantas, E.
    Syrigos, K.
    Krikelis, D.
    Markouri, A.
    Geitona, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A451 - A451
  • [44] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
    Kang, Jin
    Chen, Hua-Jun
    Zhang, Xu-Chao
    Su, Jian
    Zhou, Qing
    Tu, Hai-Yan
    Wang, Zhen
    Wang, Bin-Chao
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Ding, Yan
    Wu, Xue
    Wang, Mei
    Fu, Jian-Gang
    Yang, Zhenfan
    Zhang, Xian
    Shao, Yang W.
    Wu, Yi-Long
    Yang, Jin-Ji
    [J]. THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
  • [45] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    [J]. CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [46] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
  • [47] Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
    Zhu, Zhouyu
    Chai, Ying
    [J]. MEDICINE, 2017, 96 (45)
  • [48] Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
    Liu, Maobai
    Zhang, Longfeng
    Huang, Qishu
    Li, Na
    Zheng, Bin
    Cai, Hongfu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9195 - 9201
  • [49] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
  • [50] Ceritinib: a new drug for crizotinib-resistant ALK-positive non-small-cell lung cancer
    Hargrave, Emily
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (03) : 235 - 235
12345